PUBLISHER: DelveInsight | PRODUCT CODE: 1226638
PUBLISHER: DelveInsight | PRODUCT CODE: 1226638
"RITUXAN Drug Insight and Market Forecast - 2032" report provides comprehensive insights about RITUXAN for Rheumatoid Arthritis in the 7MM. A detailed picture of the RITUXAN for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the RITUXAN for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RITUXAN market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
RITUXAN (Rituximab) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. It was originally approved by the US FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), but has now been approved for a variety of conditions.
The primary patent for rituximab has expired. In the US, Europe, and Japan, the first bio similar version of RITUXAN was launched in late 2019, mid-2017, and 2018, respectively. The secondary patent rights for subcutaneous formulations of MabThera/RITUXAN expire beyond 2025.
RITUXAN was the first drug to target a specific B immune cell believed to play a role in inflammation in Rheumatoid Arthritis (RA) patients.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
RITUXAN Analytical Perspective by DelveInsight
This report provides a detailed market assessment of RITUXAN in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of RITUXAN for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions